Fig. 6 | Scientific Reports

Fig. 6

From: Topical application of the HSP90 inhibitor 17-AAG reduces skin inflammation and partially restores microbial balance: implications for atopic dermatitis therapy

Fig. 6

Elevated Activity of HSP90 and EPX in Leukocytes of Individuals with AD. (a) Relative HSP90 homolog expression measured in duplicate from 10 consecutive tape strips sampled from lesional and non-lesional skin of patients with AD. Data are expressed as mean ± SEM (with individual values). (b) HSP90 isoform level relative to total protein content of peripheral blood mononuclear cells. (c) HSP90 isoform level relative to total protein content of polymorphonuclear leukocytes. Both cell populations were derived from patients with AD and age- and gender-matched healthy individuals. Data are expressed as box-and-whisker plots (Tukey). (d) ELISA results showing acetyl-HSP90AA levels in PBMCs from AD patients compared to age- and gender-matched healthy controls. (e) β-Actin-corrected levels of acetyl-HSP90 in activated (TNF-α/IFN-γ, 10 ng/mL) human keratinocyte (HaCaT) cells treated with 0.1% DMSO or non-toxic concentrations of 17-AAG, analyzed by Western blot with representative bands presented. (f) Eosinophil peroxidase (EPX) activity in PMNs from AD patients and age- and gender-matched healthy controls. Data are expressed as box-and-whisker plots (Tukey) or mean ± SD. * P < 0.05, ** P < 0.01. ns, no significance.

Back to article page